All In Biotech

Drug Trial Radar · NCT03484923

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Sep 10, 2018

Primary completion

Dec 30, 2022

Study completion Dec 30, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Conditions

  • Melanoma

Interventions

  • PDR001Drug

    400 mg of PDR001 administered every 4 weeks intravenously

  • LAG525Drug

    600 mg of LAG525 administered every 4 weeks intravenously

  • INC280Drug

    400 mg of INC280 administered twice daily orally

  • ACZ885Drug

    200 mg of ACZ885 administered every 4 weeks subcutaneosuly

  • LEE011Drug

    600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Up to 49 months (randomized section) and 18 months (non-randomized section)

Locations

30 sites in 10 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • UCSF Medical Center .

    San Francisco, California

  • Massachusetts General Hospital Massachusetts Gen. Hospital CC

    Boston, Massachusetts

  • NYU Laura and Isaac Perlmutter Cancer Center Perlmutter Cancer Center

    New York, New York

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    North Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Rotterdam, Netherlands

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Manchester, United Kingdom

  • Novartis Investigative Site

    Northwood, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.